Drugs / Moxifloxacin
Moxifloxacin
DrugMoxifloxacin is a fluoroquinolone antibacterial agent used for specific susceptible bacterial infections. Labeling contains boxed warnings for disabling adverse reactions and recommends reserving use for situations where benefits outweigh risks or where no alternatives exist for some uncomplicated infections. It is a human prescription antibacterial drug.
- Trials
- 555
- Recruiting
- 21
- Completed
- 451
- With results
- 130
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 1 | 1 | — | — | — | 2 |
| Phase 1 | 3 | — | 2 | 304 | 8 | 6 | 1 | 4 | 328 |
| Phase 1/2 | 1 | — | — | 2 | — | — | — | — | 3 |
| Phase 2 | 2 | 4 | — | 29 | 5 | 1 | — | 2 | 43 |
| Phase 2/3 | 2 | 1 | 1 | 5 | — | — | — | 1 | 10 |
| Phase 3 | 8 | 1 | 1 | 41 | 4 | 3 | 1 | 7 | 66 |
| Phase 4 | 3 | — | — | 43 | 6 | — | — | 4 | 56 |
| Not applicable | 1 | 5 | 1 | 11 | 4 | 1 | — | 5 | 28 |
| Unknown | 1 | — | — | 15 | 2 | — | — | 1 | 19 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | — | 3 | 2 | 17 | 3 | 6 | 1 | — | 1 | 33 |
| Tuberculosis, Pulmonary | — | — | — | 13 | 6 | 9 | — | 1 | 1 | 30 |
| Pneumonia | — | — | — | 2 | — | 8 | 1 | — | 2 | 13 |
| Tuberculosis, Multidrug-Resistant | — | — | — | 2 | 6 | 4 | — | — | 1 | 13 |
| Community-Acquired Pneumonia | — | — | — | — | — | 6 | 4 | — | 2 | 12 |
| Pulmonary Disease, Chronic Obstructive | — | 6 | — | — | — | 3 | 3 | — | — | 12 |
| Cataract | — | — | 1 | 1 | — | 1 | 8 | — | — | 11 |
| Infections | — | 5 | — | 2 | — | 3 | — | 1 | — | 11 |
| Bacterial Infections | — | 3 | — | 1 | — | 1 | 4 | 1 | — | 10 |
| Bronchitis, Chronic | — | — | — | — | — | 2 | 1 | — | 4 | 7 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Bayer | 34 | 13 |
| 2 | Pfizer | 20 | 1 |
| 3 | Boehringer Ingelheim | 17 | 0 |
| 4 | GlaxoSmithKline | 17 | 0 |
| 5 | AstraZeneca | 16 | 0 |
| 6 | Janssen Research & Development, LLC | 13 | 0 |
| 7 | Eli Lilly and Company | 10 | 0 |
| 8 | Bristol-Myers Squibb | 9 | 0 |
| 9 | Alcon Research | 8 | 3 |
| 10 | Global Alliance for TB Drug Development | 7 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Moxifloxacin | 555 |
| 2 | Pyrazinamide | 34 |
| 3 | Isoniazid | 31 |
| 4 | Rifampin | 30 |
| 5 | bedaquiline | 28 |
| 6 | Ethambutol | 27 |
| 7 | Linezolid | 27 |
| 8 | Levofloxacin | 26 |
| 9 | pretomanid | 19 |
| 10 | Metronidazole | 17 |
Evidence
- Results reported
- 28.8%130 of 451 completed
- Published
- 10%45 of 451 completed
- Primary endpoint met
- 38%87 of 229 analyses
- Median months to report
- 19
Documents disclosed
Trial profile
- Median enrollment
- 64
- Median duration
- 7.6months
- Countries
- 93
- Study sites
- 3035
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 24
- Phase 1
- 54
- Phase 1/2
- 94
- Phase 2
- 90
- Phase 2/3
- 294
- Phase 3
- 404
- Phase 4
- 77
- Not applicable
- 102
- Unknown
- 1189
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Austin | United States | 27 |
| 2 | Baltimore | United States | 25 |
| 3 | Tempe | United States | 25 |
| 4 | London | United Kingdom | 24 |
| 5 | Cape Town | South Africa | 21 |
| 6 | Johannesburg | South Africa | 21 |
| 7 | Beijing | China | 20 |
| 8 | Berlin | Germany | 19 |
| 9 | Durban | South Africa | 19 |
| 10 | Miami | United States | 17 |
Terminations
- Terminated
- 30
- Withdrawn
- 11
- Suspended
- 2
- Stopped for recruitment
- 1.4%8 of 555 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07014735 Terminated | Terminated | The study is being terminated early on the grounds of futility, as continuation of the study is no longer considered scientifically or operationally justified. | 2026-05-31 |
| NCT04204122 Withdrawn | Withdrawn | Investigator decided to close study | 2025-03-31 |
| NCT05977868 Terminated | Terminated | DSMB recommendation based on safety benefit in Experimental (oral) arm | 2025-02-14 |
| NCT02590523 Suspended | Suspended | Lack of antibiotic availability | 2024-01-31 |
| NCT05758818 Terminated | Terminated | sponsor decision | 2023-06-08 |
| NCT05668936 Terminated | Terminated | Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile. | 2023-03-10 |
| NCT05309902 Withdrawn | Withdrawn | Study not needed | 2022-12-06 |
| NCT02359331 Terminated | Terminated | 2022-12-01 | |
| NCT04126343 Terminated | Terminated | Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures | 2020-05-22 |
| NCT01936480 Terminated | Terminated | Recruitment difficulties | 2019-06-19 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: